Idaho Clinical Trials Report — April 2026

For Idaho residents considering participation in clinical research, April 2026 brings a critical reminder: some valuable opportunities are closing soon. Across the state, 20 clinical trials are slated to conclude enrollment within the next 90 days. This includes a crucial chance for healthy volunteers, with 1 of these rapidly closing studies still seeking participants without specific health conditions. Individuals interested in contributing to medical advancements, especially in areas with impending deadlines, should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face limited time to join research studies. Trials focused on various forms of cancer, respiratory conditions, and dermatological issues are among those with enrollment windows closing soon. Conditions with trials nearing their end include:

• Asthma
• Stage IV lung cancer AJCC V8
• Anatomic stage III breast cancer AJCC V8
• Atopic dermatitis
• Chronic granulomatous disease (CGD)
• COPD
• Endometrial adenocarcinoma
• Diabetic peripheral neuropathic pain
• Endometrial clear cell adenocarcinoma
• Endometrial dedifferentiated carcinoma

These studies represent diverse areas of medical inquiry, offering participants the chance to engage with research that could lead to new treatments or better understandings of these conditions. Acting quickly is essential to be considered for these trials.

A Focused New Opportunity: Addressing Lung Health in People with HIV

This April, Idaho saw the launch of 1 new clinical trial, a more focused opening compared to the 2 new trials that began in March 2026. While the number of new studies is modest this month, the newly opened trial addresses a significant health challenge, particularly for older adults.

The notable new trial is NCT07507435, titled "Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults." Sponsored by the Seattle Institute for Biomedical and Clinical Research, this study aims to enroll 480 participants. It focuses on people with HIV (PWH) who continue to face an elevated risk of community-acquired pneumonia, even with effective antiretroviral therapy. Pneumonia can lead to serious complications, including hospitalization, respiratory failure, cardiovascular issues, long-term decline in lung function, and increased mortality.

This research seeks to evaluate how pharmacist-led proactive e-consults might improve medication management and, in turn, lung health outcomes for this vulnerable population. The trial is open to older adults, ensuring that this demographic, often disproportionately affected by health complications, has an opportunity to participate in this important research.

Idaho's Research Landscape: Geographic Reach and Overall Activity

Despite a quieter month for new trial openings, Idaho maintains a robust research environment with a total of 330 clinical trials currently recruiting. These studies are spread across 24 cities and involve 192 research sites throughout the state, indicating broad accessibility for potential participants.

The single new trial this month is located in Boise, reinforcing the capital city's role as a hub for medical research. While new opportunities may sometimes concentrate in larger metropolitan areas, the overall distribution of ongoing trials ensures that residents in various parts of Idaho have access to research opportunities. This widespread presence means individuals don't always have to travel far to find a study that matches their interests or health needs.

The conditions being investigated in the new trial this month are specific and impactful, focusing on HIV and pneumonia. Other areas of research that saw new trials open in previous months, but not this month, included inhaled corticosteroid use, proton pump inhibitor effects, and smoking cessation, demonstrating the diverse range of health topics that clinical research in Idaho addresses over time.

Participation Opportunities: Healthy Volunteers and Specific Demographics

For individuals without a specific medical condition, opportunities to contribute to medical science are available across Idaho. While the single new trial launched this month does not accept healthy volunteers, there are still 24 total clinical trials currently recruiting healthy participants statewide. These studies play a vital role in establishing baseline data and evaluating new treatments in healthy populations, making their contribution invaluable.

Regarding specific demographics, the new trial for optimizing medications and lung health in people with HIV is inclusive of older adults. This is a significant aspect, as research involving older populations is crucial for understanding age-related health issues and ensuring treatments are effective and safe for all age groups. This month, 1 new trial includes older adults, while no new trials are specifically designed for children, female-only, or male-only participants.

The Seattle Institute for Biomedical and Clinical Research, an "OTHER" type of sponsor (neither purely industry nor academic in the provided data), is driving this month's new research, highlighting the varied organizations contributing to Idaho's clinical trial landscape.

As we look forward, the ongoing enrollment in Idaho's existing 330 trials, coupled with the critical deadlines for studies closing soon, underscores the continuous need for participant engagement. Future months will undoubtedly bring new research avenues, but the immediate focus remains on maximizing the impact of current and soon-to-close studies.